Holen Sie sich die Stockscreener-App
1.24
7.46%
-0.10
Scienture Holdings Inc Aktie (SCNX) Neueste Nachrichten
Investors: What’s The Real Deal With Scienture Holdings Inc (NASDAQ: SCNX) - Stocks Register
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization - The Manila Times
Scienture Gears Up for Major Product Launch: New CCO and Syneos Health Partnership Signal Growth - Stock Titan
3 Reasons APG is Risky and 1 Stock to Buy Instead - The Globe and Mail
Scienture Holdings Announces FDA Approval for ArbliTM - TipRanks
Lucid (LCID): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Scienture Holdings announces draw on Equity Line of Credit - MSN
Scienture announces draaw on Equity Line of Credit - TipRanks
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Manila Times
Organovo Announces Reverse Stock Split - The Manila Times
FDA Approves Revolutionary Liquid Losartan: Scienture's Game-Changing Hypertension Treatment - StockTitan
Scienture announces U.S. FDA approval of NDA for SCN-102 - TipRanks
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
FDA Approves Losartan Potassium for Reduction in Risk of Stroke - Drug Topics
What's Going On With Scienture Shares Tuesday? - Benzinga
FDA Approves SCN-102, Liquid Oral Suspension Formulation of Losartan - Pharmacy Times
Pre-Market Momentum: Scienture (SCNX) Stock Soars After FDA Green Light - Stocks Telegraph
Scienture Says US FDA Approves Oral Liquid Formulation of Hypertension Drug Losartan - MarketScreener
SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024. - The Manila Times
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Breakthrough FDA Approval: First-Ever Liquid Hypertension Drug Targets $1.5B Market - StockTitan
Billionaires Ray Dalio and Paul Tudor Jones Are Piling Into a Hard Asset That Has Trounced Nvidia This Year - The Globe and Mail
Q4 Earnings Outperformers: D.R. Horton (NYSE:DHI) And The Rest Of The Home Builders Stocks - The Globe and Mail
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
4 Quantum Computing Stocks on Watch Today as GTC 2025 Kicks Off - The Globe and Mail
Scienture Holdings Inc (SCNX) Stock Behavior Isn’t As Predictable As You Think - Stocks Register
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Scienture Holdings appoints new CFO, stockholders vote at annual meeting By Investing.com - Investing.com Australia
Scienture Holdings appoints new CFO, stockholders vote at annual meeting - Investing.com
Scienture Holdings Appoints New CFO Eric Sherb - TipRanks
Public market insider buying at ATS Corp. (ATS) - The Globe and Mail
Scienture Holdings Secures Exclusive Naloxone Agreement - TipRanks
United States shares higher at close of trade; Dow Jones Industrial Average up 0.52% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.52% - Investing.com
Best Stocks Under $5 Right Now - Benzinga
Nasdaq Down Over 400 Points; Kroger Posts Upbeat Earnings - Benzinga
What's Going On With Scienture Stock Thursday? - Benzinga
Scienture Unit, Summit Biosciences Collaborate to Launch Naloxone Spray for Opioid Overdose Treatment in the US - Marketscreener.com
Dow Tumbles 1%; US Initial Jobless Claims DeclineAclarion (NASDAQ:ACON), AGM Gr Hldgs (NASDAQ:AGMH) - Benzinga
Scienture (SCNX) Soars In Pre-Hour Trading After Strategic Business Development - Stocks Telegraph
SCNX Stock Price and Chart — NASDAQ:SCNX - TradingView
Scienture To Commercially Launch Rezenopy -March 06, 2025 at 08:03 am EST - Marketscreener.com
Scienture Holdings rises on launch of opioid overdose antidote Rezenopy - TradingView
SCIENTURE to commercially launch REZENOPY®, a life-saving - GlobeNewswire
Can This New High-Strength Naloxone Treatment Transform the $189M Opioid Crisis Market? - StockTitan
Nova Scotia groups want free Canadian trade as poll shows support in Atlantic region - Yahoo Canada Finance
Scienture Holdings (FRA:4E4) Preferred Stock : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
Biotech Stocks Facing FDA Decision In March 2025 - RTTNews
FDA Accepts New Drug Application for Vatiquinone to Treat Friedreich Ataxia - Drug Topics
Definity Financial Corporation Chief Executive Officer Rowan Saunders to hold virtual fireside chat with BMO Capital Markets - Yahoo Canada Finance
Stock market today: Wall Street finishes mixed as strong fashion, tobacco stocks offset Ford's drop - Yahoo Canada Finance
MATÉRIAUX PONT-MASSON RETURNS TO RONA'S NETWORK OF AFFILIATED DEALERS - Yahoo Canada Finance
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga India
Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s - GlobeNewswire
Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics - The Manila Times
Scienture President to Keynote at Major SSX Pharma Conference, Spotlight Innovation Strategy - StockTitan
Scienture Holdings Board Restructures After Director Resignations - TipRanks
Scienture Holdings, Inc. Announces Director Resignations -January 17, 2025 at 04:05 pm EST - Marketscreener.com
Scienture Holdings Faces Nasdaq Compliance Challenge - TipRanks
0.97%
9.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):